Fibroblast Growth Factors

2. Auflage 2023
ISBN: 978-0-443-15793-6
Verlag: Elsevier Science

Buch, Englisch, 880 Seiten, Format (B × H): 278 mm x 214 mm, Gewicht: 2760 g

Fibroblast Growth Factors, Second Edition systematically introduces readers to FGF in the fields of injury repair and regeneration, endocrinology and metabolism, structure and modification, pharmaceutics, pharmacology, FGF/FGFR inhibitor, engineering and new drug development. Fibroblast growth factors (FGFs) are secreted protein ligands that act in a paracrine or endocrine fashion to carry out their pleiotropic functions in development, tissue homeostasis and metabolism. This book covers the work from Li's team from 2013 to 2018 and will be a primer for scientists, particularly young students entering the FGFs field with an eye on basic research and application.

Zielgruppe

<p>Scientists who are working in Fibroblast Growth Factors (FGFs) basic research and engineering field;  </p> <p>Clinical practitioners who are working in wound healing, surgery, emergency, and diabetes; </p> <p>Postgraduate students whose major is pharmacology, biopharmacology.</p> <p>Scientists who are engaged in new drug development in biopharmacological companies. Biopharmacology course for postgraduate students.</p> <p>Doctors and clinical researcher who are interesting in FGF. </p>

Autoren/Hrsg.

Li, Xiaokun

Fachgebiete

• Naturwissenschaften Biowissenschaften Proteinforschung
• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

1. Growth Factors Reviews 2. Injury repair and Regeneration 3. Endocrinology and Metabolism 4. Structure and Modification 5. Signaling Pathway and Pharmacology 6. Pharmaceutics and New Material 7. Bioreactor and Engineering 8. FGF/FGFR and Inhibitors 9. Others

Über Autor(innen)

Li, Xiaokun
Xiaokun Li is Professor at Wenzhou Medical University, and has been vice director and associate professor at the Bioengineering Institute at Jinan University, China. He was among the first to study FGFs in China, and leads the largest dedicated research group in the world on the subject. In the past 20 years he has had new drugs and products approved by China SFDA. He has published 183 papers in leading international journals, and is the chair of the International Chinese FGF Association. He holds a PhD from Sun-Yat sen Medical University, and a degree in medical science from Norman Bethune Medical University in China.